Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Why Is Radius Health (RDUS) Down 2.7% Since The Last Earnings Report?

By Zacks Investment ResearchStock MarketsMay 31, 2017 09:02PM ET
www.investing.com/analysis/why-is-radius-health-(rdus)-down-2.7-since-the-last-earnings-report-200192615
Why Is Radius Health (RDUS) Down 2.7% Since The Last Earnings Report?
By Zacks Investment Research   |  May 31, 2017 09:02PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

It has been about a month since the last earnings report for Radius Health, Inc. (NASDAQ:RDUS) . Shares have lost about 2.7% in that time frame, underperforming the market .

Will the recent negative trend continue leading up to the stock's next earnings release, or is it due for a breakout? Before we dive into how investors and analysts have reacted of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.

Radius Health Posts Wider Q1 Loss, Tymlos Approved

Radius posted a loss of $1.32 per share in the first quarter of 2017, compared with a loss of $0.94 per share in the year-ago quarter and wider than the Zacks Consensus Estimate loss of $1.25. The year-over-year increase in net loss was attributable to an increase in general and administrative expenses.

Quarter in Detail

Research and development expenses for the reported quarter were $19.5 million, down 28.9% year over year. The decline was attributed to a decrease in Tymlos/abaloparatide-SC, abaloparatide-TD and elacestrant program development costs, partially offset by an increase in RAD140 development costs.

General and administrative expenses for the reported quarter jumped to $38.1 million from $13.6 million. The increase came on the back of growth in professional support costs, including the costs associated with increasing headcount for the commercialization of Tymlos, including the completion of the build out of the commercial organization in the first quarter of 2017. This increase was also driven by an increase in compensation expenses, including stock-based compensation, due to an increase in headcount.

Pipeline Update

On Apr 28, the FDA approved Radius Health’s lead drug Tymlos (abaloparatide) injection for the treatment of postmenopausal women with high risk osteoporosis for fracture – defined as history of osteoporotic fracture – multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. It is currently under review in the EU. The company expects an opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use in Jul 2017.

The company is also developing abaloparatide-transdermal as a short wear-time transdermal patch. The company posted positive results from the trial in Sep 2016. The company is currently focused on completing the manufacturing, scale up, and other required activities needed to initiate a pivotal study to evaluate bioequivalence to abaloparatide-SC.

The company also completed enrolment in its ongoing phase I studies of elacestrant in advanced metastatic breast cancer. Radius Health reported encouraging results from its ongoing phase I studies. The company plans to take the next steps for the program in the first half of 2017, which would include the design of a phase II trial. Additionally, it anticipates reporting results from its completed phase IIb trial in vasomotor symptoms in the first half of 2017.

Furthermore, the company submitted an investigational new drug application to the FDA for RAD140, which is a selective androgen receptor modulator. The application has been accepted. Moving ahead, it expects to commence a first-in-human phase I study in women with hormone receptor positive breast cancer in 2017.

How Have Estimates Been Moving Since Then?

Following the release, investors have witnessed a downward trend in fresh estimates. There has been one revision higher for the current quarter compared to two lower. In the past month, the consensus estimate has shifted lower by 89.6% due to these changes.

Radius Health, Inc. Price and Consensus

VGM Scores

At this time, Radius Health's stock has a subpar Growth Score of 'D', though it is lagging a bit on the momentum front with an 'F'. Following the exact same course, the stock was allocated a grade of 'F' on the value side, putting it in the fifth quintile for this investment strategy.

Overall, the stock has an aggregate VGM Score of 'F'. If you aren't focused on one strategy, this score is the one you should be interested in.

Our style scores indicate investors will probably be better served looking elsewhere.

Outlook

Estimates have been broadly trending downward for the stock. The magnitude of this revision also indicates a downward shift. Notably, the stock has a Zacks Rank #3 (Hold). We expect in-line returns from the stock in the next few months.



Radius Health, Inc. (RDUS): Free Stock Analysis Report

Original post
Why Is Radius Health (RDUS) Down 2.7% Since The Last Earnings Report?
 

Related Articles

Why Is Radius Health (RDUS) Down 2.7% Since The Last Earnings Report?

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email